A pilot study to evaluate the efficacy of compression therapy using stockings and sleeves for nab-paclitaxel/gemcitabine-induced peripheral neuropathy in unresectable pancreatic cancer patients.

A pilot study to evaluate the efficacy of compression therapy using stockings and sleeves for nab-paclitaxel/gemcitabine-induced peripheral neuropathy in unresectable pancreatic cancer patients. - A pilot study to evaluate the efficacy of compression therapy using stockings and sleeves for nab-paclitaxel/gemcitabine-induced peripheral neuropathy in unresectable pancreatic cancer patients.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019482

Enrollment

Registered

2015-10-23

Start date

2015-10-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable pancreatic cancer

Interventions

Compression therapy using stockings and sleeves

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Pathologically diagnosed Adenocarcinoma or Adenosquamous carcinoma (2) Unresectable (3) No prior chemotherapy for pancreatic cancer (4) Scheduled to receive nab-paclitaxel / gemcitabine (5) Aged 20- (6) Performance Status (PS) 0-1 (7) Patients are judged by investigators with adequate organ function within two weeks (8) Without history or complication of peripheral neuropathy (9) With written informed consent

Exclusion criteria

Exclusion criteria: (1) No prior therapy using oxaliplatin (2) Intestinal pneumonitis or pulmonary fibrosis (3) Active infection (4) Active double cancer (5) With allergy for material of stockings and sleeves (6) Using elastic stocking regularly (7) With server artery dysfunction and congestive heart failure, just after dermal graft, necrosis, sever edema, suppurative disease on the skin (8) With extreme leg deformity (9) Administering medicine for thrombosis (10) Severe nervous disorder or mental disorder. (11) History of serious drug hypersensitivity or a history of drug allergy (12) Severe complications (13) Pregnancy (14) Physician concludes that the patient's participation in this trial is inappropriate

Design outcomes

Primary

Measure	Time frame
The incidence and the level of peripheral neuropathy after 16 weeks.	—

Countries

Japan

Contacts

Public ContactMasayo Motoya

Sapporo Medical University Department of Gastroenterology Rheumatology and Clinical Immunology

hmasayo@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026